...
首页> 外文期刊>British Journal of Cancer >Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas
【24h】

Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas

机译:甲状腺癌中细胞周期蛋白依赖性蛋白激酶抑制剂p21(WAF1 / CIP1)基因缺失的证据

获取原文

摘要

Eukaryotic cell cycle progression is controlled by a host of cyclin/cyclin-dependent kinases (Cdks), that are themselves regulated by multiple factors, including a group of small cyclin-Cdk inhibitor proteins (p15, p16, p21 and p27). The involvement of Cdk inhibitors in carcinogenesis has been demonstrated by the studies of p16. p53 is frequently mutated in thyroid carcinomas and p21/Waf1 is a downstream effector of p53. It is conceivable that genetic defects of genes downstream in the p53 pathway could also be oncogenic. We, therefore, examined a series of 57 thyroid tumour specimens (eight follicular adenomas and 49 carcinomas) for deletion and point mutation of the p21/Waf1 gene. Three different kinds of deletions ranging from 349 to 450 bp were detected in five papillary carcinoma specimens by reverse transcription-polymerase chain reaction (RT-PCR). All the deletions were involved in the second exon of the p21/Waf1 gene. RT-PCR single strand conformational polymorphism (SSCP) analysis of remaining samples failed to reveal any point mutations in the coding region of the gene, except for a polymorphism at codon 31 (Ser to Arg). Genomic Southern blot analysis did not demonstrate any gene deletion or rearrangement in these samples, indicating abnormal RNA splicing may be involved. Analysis of intron-exon boundary and the coding region of the second exon did not reveal any mutation except for a point mutation (C to G) located 16 bp downstream from the splice donor site of the second intron in three out of five samples with p21/Waf1 deletions. Whether the mutation plays any role in aberrant RNA splicing remains to be determined. Among the five samples with p21/Waf1 gene deletions, none of them simultaneously carried a p53 or retinoblastoma (Rb) gene mutation. No p21/Waf1 abnormality was found in the benign adenomas. Thus, 12.5% (5/40) of thyroid papillary carcinoma specimens harboured p21/Waf1 gene deletions. Our data suggest that p21/Waf1 gene deletion is involved in thyroid carcinogenesis and may play an important role in thyroid cell transformation.
机译:真核细胞周期的进展受许多细胞周期蛋白/细胞周期蛋白依赖性激酶(Cdks)的控制,这些激酶本身受多种因素调节,包括一组小的细胞周期蛋白-Cdk抑制剂蛋白(p15,p16,p21和p27)。 p16的研究已证明Cdk抑制剂参与了癌变。 p53在甲状腺癌中经常发生突变,而p21 / Waf1是p53的下游效应子。可以想象,p53途径下游基因的遗传缺陷也可能是致癌的。因此,我们检查了一系列57个甲状腺肿瘤标本(8个滤泡状腺瘤和49个癌)中p21 / Waf1基因的缺失和点突变。通过逆转录-聚合酶链反应(RT-PCR)在五个乳头状癌标本中检测到三种不同类型的缺失,范围从349至450 bp。所有的缺失都与p21 / Waf1基因的第二个外显子有关。其余样品的RT-PCR单链构象多态性(SSCP)分析未能揭示基因编码区中的任何点突变,除了密码子31的多态性(Ser至Arg)。基因组Southern印迹分析未显示这些样品中有任何基因缺失或重排,表明可能涉及异常的RNA剪接。对内含子-外显子边界和第二个外显子的编码区的分析未发现任何突变,除了在p21的五个样本中有三个位于第二个内含子的剪接供体位点下游16 bp处的点突变(C到G)之外/ Waf1删除。该突变是否在异常RNA剪接中发挥任何作用仍有待确定。在五个具有p21 / Waf1基因缺失的样本中,没有一个样本同时携带p53或视网膜母细胞瘤(Rb)基因突变。在良性腺瘤中未发现p21 / Waf1异常。因此,甲状腺乳头状癌标本中有12.5%(5/40)含有p21 / Waf1基因缺失。我们的数据表明,p21 / Waf1基因缺失与甲状腺癌发生有关,并且可能在甲状腺细胞转化中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号